For publicly traded healthcare companies, clinical trial data and milestone disclosure can present great opportunities as well as significant challenges.
On the path toward regulatory approval, life science and medical device company management will encounter difficult disclosure decisions surrounding clinical and regulatory events. Finding the right balance between the “duty to disclose” vs. “pressure to disclose” dilemma is not easy. If done right, such milestones are a great way to raise visibility within the investment, clinical and scientific communities. If done wrong, the consequences may be severe.